Simon C Mendelsohn

Dr. Simon C Mendelsohn

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
APAdam Penn-Nicholson
Adam Penn-Nicholson
SMStanley Kimbung Mbandi
Stanley Kimbung Mbandi
ETEthan Thompson
Ethan Thompson
SMSimon C Mendelsohn
Simon C Mendelsohn
SSSARA SULIMAN
SARA SULIMAN
TSThomas J. Scriba
Thomas J. Scriba
Improved tuberculosis diagnostics and tools for monitoring treatment response are urgently needed. We developed a robust and simple, PCR-based host-blood transcriptomic signature, RISK6, for multiple applications: identifying individuals at risk of incident disease, as a screening test for subclinical or clinical tuberculosis, and for monitoring tuberculosis treatment. RISK6 utility was validated by blind prediction using quantitative real-time (qRT) PCR in seven independent cohorts. Prognostic performance significantly exceeded that of previous signatures discovered in the same cohort. Performance for diagnosing subclinical and clinical disease in HIV-uninfected and HIV-infected persons, assessed by area under the receiver-operating characteristic curve, exceeded 85%. As a screening test for tuberculosis, the sensitivity at 90% specificity met or approached the benchmarks set out in World Health Organization target product profiles for non-sputum-based tests. RISK6 scores correlated with lung immunopathology activity, measured by positron emission tomography, and tracked treatment response, demonstrating utility as treatment response biomarker, while predicting treatment failure prior to treatment initiation. Performance of the test in capillary blood samples collected by finger-prick was noninferior to venous blood collected in PAXgene tubes. These results support incorporation of RISK6 into rapid, capillary blood-based point-of-care PCR devices for prospective assessment in field studies.

21 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HMHumphrey Mulenga
Humphrey Mulenga
CZChambrez-Zita Zauchenberger
Chambrez-Zita Zauchenberger
EBErick W. Bunyasi
Erick W. Bunyasi
SMStanley Kimbung Mbandi
Stanley Kimbung Mbandi
SMSimon C Mendelsohn
Simon C Mendelsohn
MHMark Hatherill
Mark Hatherill
Host blood transcriptomic biomarkers have potential as rapid point-of-care triage, diagnostic, and predictive tests for Tuberculosis disease. We aimed to summarise the performance of host blood transcriptomic signatures for diagnosis of and prediction of progression to Tuberculosis disease; and compare their performance to the recommended World Health Organisation target product profile. A systematic review and meta-analysis of the performance of host blood mRNA signatures for diagnosing and predicting progression to Tuberculosis disease in HIV-negative adults and adolescents, in studies with an independent validation cohort. Medline, Scopus, Web of Science, and EBSCO libraries were searched for articles published between January 2005 and May 2019, complemented by a search of bibliographies. Study selection, data extraction and quality assessment were done independently by two reviewers. Meta-analysis was performed for signatures that were validated in ≥3 comparable cohorts, using a bivariate random effects model. Twenty studies evaluating 25 signatures for diagnosis of or prediction of progression to TB disease in a total of 68 cohorts were included. Eighteen studies evaluated 24 signatures for TB diagnosis and 17 signatures met at least one TPP minimum performance criterion. Three diagnostic signatures were validated in clinically relevant cohorts to differentiate TB from other diseases, with pooled sensitivity 84%, 87% and 90% and pooled specificity 79%, 88% and 74%, respectively. Four studies evaluated signatures for progression to TB disease and performance of one signature, assessed within six months of TB diagnosis, met the minimal TPP for a predictive test for progression to TB disease. Host blood mRNA signatures hold promise as triage tests for TB. Further optimisation is needed if mRNA signatures are to be used as standalone diagnostic or predictive tests for therapeutic decision-making.

1 April 2019 in Cell Reports
Verified
Journal Article
Open access
PRPramila Rijal
Pramila Rijal
SESean C. Elias
Sean C. Elias
SMSamara Rosendo Machado
Samara Rosendo Machado
JXJulie Xiao
Julie Xiao
LSLisa Schimanski
Lisa Schimanski
ATAlain R. Townsend
Alain R. Townsend
We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP) and boosted with modified vaccinia virus Ankara. Among 82 antibodies isolated from peripheral blood B cells, almost half neutralized GP pseudotyped influenza virus. The antibody response was diverse in gene usage and epitope recognition. Although close to germline in sequence, neutralizing antibodies with binding affinities in the nano- to pico-molar range, similar to "affinity matured" antibodies from convalescent donors, were found. They recognized the mucin-like domain, glycan cap, receptor binding region, and the base of the glycoprotein. A cross-reactive cocktail of four antibodies, targeting the latter three non-overlapping epitopes, given on day 3 of EBOV infection, completely protected guinea pigs. This study highlights the value of experimental vaccine trials as a rich source of therapeutic human monoclonal antibodies.

10 March 2022 in Communications Medicine
Verified
Journal Article
Open access
PDF file
SMSimon C Mendelsohn
Simon C Mendelsohn
SMStanley Kimbung Mbandi
Stanley Kimbung Mbandi
AFAndrew Fiore-Gartland
Andrew Fiore-Gartland
APAdam Penn-Nicholson
Adam Penn-Nicholson
MMMunyaradzi Musvosvi
Munyaradzi Musvosvi
TSThomas J. Scriba
Thomas J. Scriba
Background: Sensitive point-of-care screening tests are urgently needed to identify individuals at highest risk of tuberculosis. We prospectively tested performance of host-blood transcriptomic tuberculosis signatures.Methods: Adults without suspicion of tuberculosis were recruited from five endemic South African communities. Eight parsimonious host-blood transcriptomic tuberculosis signatures were measured by microfluidic RT-qPCR at enrolment. Upper respiratory swab specimens were tested with a multiplex bacterial-viral RT-qPCR panel in a subset of participants. Diagnostic and prognostic performance for microbiologically confirmed prevalent and incident pulmonary tuberculosis was tested in all participants at baseline and during active surveillance through 15 months follow-up, respectively.Results: Among 20,207 HIV-uninfected and 963 HIV-infected adults screened; 2923 and 861 were enroled. There were 61 HIV-uninfected (weighted prevalence 1.1%) and 10 HIV-infected (prevalence 1.2%) tuberculosis cases at baseline. Parsimonious signature diagnostic performance was superior among symptomatic (AUCs 0.85–0.98) as compared to asymptomatic (AUCs 0.61–0.78) HIV-uninfected participants. Thereafter, 24 HIV-uninfected and 9 HIV-infected participants progressed to incident tuberculosis (1.1 and 1.0 per 100 person-years, respectively). Among HIV-uninfected individuals, prognostic performance for incident tuberculosis occurring within 6–12 months was higher relative to 15 months. 1000 HIV-uninfected participants were tested for respiratory microorganisms and 413 HIV-infected for HIV plasma viral load; 7/8 signature scores were higher (p < 0.05) in participants with viral respiratory infections or detectable HIV viraemia than those without.Conclusions: Several parsimonious tuberculosis transcriptomic signatures met triage test targets among symptomatic participants, and incipient test targets within 6 months. However, the signatures were upregulated with viral infection and offered poor specificity for diagnosing sub-clinical tuberculosis.

15 October 2025 in The Lancet Global Health
Verified
Journal Article
Open access
SMSimon C Mendelsohn
Simon C Mendelsohn
HMHumphrey Mulenga
Humphrey Mulenga
MTMichele Tameris
Michele Tameris
TMTumelo Moloantoa
Tumelo Moloantoa
SMStephanus T Malherbe
Stephanus T Malherbe
MHMark Hatherill
Mark Hatherill
More than half of tuberculosis cases detected by community prevalence surveys are classified as asymptomatic. We evaluated yield of symptom and chest radiograph screening of tuberculosis-exposed household contacts in South Africa. For this prospective observational cohort study, adult volunteers (aged ≥18 years) with household exposure within the past 6 months to patients with untreated or partially treated pulmonary tuberculosis, identified through local health services, were enrolled at three sites in South Africa (Worcester and Ravensmead, Western Cape Province, and Soweto, Gauteng Province). Household contacts were excluded if they were unlikely to attend study visits, or had conditions interfering with consent or study participation, including psychiatric illness, substance dependence, or incarceration. Systematic screening of tuberculosis symptoms (any duration), chest radiograph (any abnormality indicative of active tuberculosis), and sputum microscopy, Xpert Ultra, and liquid culture were performed. Serum C-reactive protein (CRP) was measured by multiplex bead array. Prevalent tuberculosis was microbiologically confirmed (Xpert Ultra or culture). Symptomatic and asymptomatic tuberculosis were defined as prevalent tuberculosis with and without reported symptoms compatible with tuberculosis. The primary outcome was the diagnostic yield (sensitivity) of microbiologically confirmed pulmonary tuberculosis. Between April 22, 2021 and Sept 22, 2022, 979 household contacts were enrolled, 345 (35·2%) male and 634 (64·8%) female, 185 (18·9%) living with HIV and 187 (19·1%) with previous tuberculosis. Prevalent tuberculosis occurred in 51 (5·2%) and was asymptomatic in 42 (82·4%) of 51. Only 13 (31·0%) of 42 asymptomatic people with tuberculosis were sputum-smear positive; eight (61·5%) of these 13 had a low bacillary burden, with smear grades scanty or 1+ (1-99 acid-fast bacilli per 100 fields). CRP did not discriminate healthy household contacts from those with asymptomatic tuberculosis (area under the curve 0·60, 95% CI 0·47-0·73). An abnormal chest radiograph suggestive of tuberculosis was observed in 23 of 41 asymptomatic (sensitivity 56·1%, 95% CI 41·0-70·1) versus eight of nine symptomatic (sensitivity 88·9%, 56·5-98·0) people with tuberculosis. Sensitivity of chest radiograph in combination with symptom screening was 32 (64·0%) of 50 (50·1-75·9) for all prevalent tuberculosis. More than 80% of confirmed people with tuberculosis among household contacts were asymptomatic; chest radiograph screening missed more than 40% of these. Community prevalence surveys reliant on symptom-based and chest radiograph-based approaches might substantially underestimate the prevalence of asymptomatic tuberculosis in endemic countries. Regional Prospective Observational Research for Tuberculosis South Africa through funding from the US National Institutes of Health, the Civilian Research and Development Foundation, and the South African Medical Research Council.

15 December 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
HMHumphrey Mulenga
Humphrey Mulenga
MMMunyaradzi Musvosvi
Munyaradzi Musvosvi
SMSimon C Mendelsohn
Simon C Mendelsohn
APAdam Penn-Nicholson
Adam Penn-Nicholson
SMStanley Kimbung Mbandi
Stanley Kimbung Mbandi
TTthe CORTIS Study Team
the CORTIS Study Team
Rationale: Performance of blood transcriptomic tuberculosis (TB) signatures in longitudinal studies and effects of TB-preventive therapy and coinfection with HIV or respiratory organisms on transcriptomic signatures has not been systematically studied. Objectives: We evaluated longitudinal kinetics of an 11-gene blood transcriptomic TB signature, RISK11, and effects of TB-preventive therapy (TPT) and respiratory organisms on RISK11 signature score, in HIV-uninfected and HIV-infected individuals. Methods: RISK11 was measured in a longitudinal study of RISK11-guided TPT in HIV-uninfected adults, a cross-sectional respiratory organisms cohort, or a longitudinal study in people living with HIV (PLHIV). HIV-uninfected RISK11+ participants were randomized to TPT or no TPT; RISK11− participants received no TPT. PLHIV received standard-of-care antiretroviral therapy and TPT. In the cross-sectional respiratory organisms cohort, viruses and bacteria in nasopharyngeal and oropharyngeal swabs were quantified by real-time quantitative PCR. Measurements and Main Results: RISK11+ status was transient in most of the 128 HIV-negative participants with longitudinal samples; more than 70% of RISK11+ participants reverted to RISK11− by 3 months, irrespective of TPT. By comparison, reversion from a RISK11+ state was less common in 645 PLHIV (42.1%). Non-HIV viral and nontuberculous bacterial organisms were detected in 7.2% and 38.9% of the 1,000 respiratory organisms cohort participants, respectively, and among those investigated for TB, 3.8% had prevalent disease. Median RISK11 scores (%) were higher in participants with viral organisms alone (46.7%), viral and bacterial organisms (42.8%), or prevalent TB (85.7%) than those with bacterial organisms other than TB (13.4%) or no organisms (14.2%). RISK11 could not discriminate between prevalent TB and viral organisms. Conclusions: Positive RISK11 signature status is often transient, possibly due to intercurrent viral infection, highlighting potentially important challenges for implementation of these biomarkers as new tools for TB control.